Sofgen Pharma director files initial Form 3

Sofgen Pharma S.A. director Manuel Jose Vial Claro filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 03/26/2026 - 04:40 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Sofgen Pharma S.A. director Manuel Jose Vial Claro filed an initial ownership report on Form 3. The filing establishes his status as a reporting person and shows no reported purchases, sales, or other transactions, with all transaction counts and share amounts indicated as zero.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Sofgen Pharma (PROCF) Form 3 for Manuel Jose Vial Claro show?

The Form 3 shows that director Manuel Jose Vial Claro has become a reporting person of Sofgen Pharma S.A. It reports zero purchases, sales, derivative exercises, gifts, or other transactions, with all transaction-related share counts listed as zero.

Are there any share purchases or sales reported in the Sofgen Pharma (PROCF) Form 3?

No share purchases or sales are reported in this Form 3. The transaction summary shows buyCount and sellCount as zero, with buyShares and sellShares also at zero, indicating no trading activity disclosed in this initial ownership filing.

Does the Sofgen Pharma (PROCF) Form 3 disclose any derivative securities for Manuel Jose Vial Claro?

The Form 3 does not list any derivative securities for Manuel Jose Vial Claro. The derivativeSummary is empty and derivativeTransactionCount is zero, meaning no options, warrants, or similar derivative positions are disclosed in this filing excerpt.

What insider activity totals are reported in the Sofgen Pharma (PROCF) Form 3?

All insider activity totals are reported as zero in this Form 3. The filing shows zero buys, sells, gifts, exercises, tax withholdings, and restructurings, with netBuySellShares at zero and netBuySellDirection labeled as neutral.

What role does Manuel Jose Vial Claro hold at Sofgen Pharma (PROCF) in this Form 3?

The Form 3 identifies Manuel Jose Vial Claro as a director of Sofgen Pharma S.A. It flags him as a director, with no officer position or ten percent owner status indicated, establishing his reporting obligation as a board member.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Vial Claro Manuel Jose

(Last) (First) (Middle)

11600 MIRAMAR PARKWAY, SUITE 300

(Street)

MIRAMAR FLORIDA 33025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Sofgen Pharma S.A. [ PROC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

See Exhibit 24 - Power of Attorney.

No securities are beneficially owned.

	/s/ Freddy Andres Lozano Reyes, attorney-in-fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)